Figure 1: Transcriptomic biosignature after CA. Microarrays were used to compare the gene expression profiles of blood cells from 21 patients with good neurological outcome (CPC 1-2) and 14 patients with poor neurological outcome (CPC 3-5) 6 months after CA. Represented is a heat-map of 582 genes differentially expressed between good outcome and poor outcome groups with a fold-change above 1.3 and a false discovery rate <5%. 70 genes were up-regulated in poor outcome group and 512 genes were up-regulated in good outcome group. Differential expression was determined using SAM software.